New research findings by Massachusetts General Hospital doctors further substantiate FDA warnings against the use of anticoagulants Xarelto and Pradaxa in atrial fibrillation (AF) patients undergoing dialysis. After review of almost 30,000 AF dialysis patients, doctors determined that the use of Xarelto and Pradaxa in patients undergoing dialysis poses a higher risk of bleeding and death than the use of more traditional treatments, such as warfarin and aspirin. In particular, while warfarin users experienced 35.9 bleeding occurrences per 100 patient years (number of incidents over time of each patient’s drug use), Pradaxa and Xarelto saw an 83.1 and 68.4 rate, respectively. That is nearly double the likelihood of bleeding for Xarelto users, with an even higher risk for those patients taking Pradaxa. Similar conclusions were drawn in the area of mortality rates. The findings underscore that the use of Xarelto and Pradaxa may be dangerous for dialysis patients, as these drugs are processed through already-compromised kidneys. Moreover, Xarelto and Pradaxa are unsafe treatments for all patients due to their lack of a reversal agent in the event of bleeding, leading to a heightened fatality rate among all users.